RU2005132458A - Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21 - Google Patents
Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21 Download PDFInfo
- Publication number
- RU2005132458A RU2005132458A RU2005132458/13A RU2005132458A RU2005132458A RU 2005132458 A RU2005132458 A RU 2005132458A RU 2005132458/13 A RU2005132458/13 A RU 2005132458/13A RU 2005132458 A RU2005132458 A RU 2005132458A RU 2005132458 A RU2005132458 A RU 2005132458A
- Authority
- RU
- Russia
- Prior art keywords
- agonist
- patient
- polypeptide
- parameter
- pharmaceutical composition
- Prior art date
Links
- 108010074108 interleukin-21 Proteins 0.000 title claims 41
- 239000000556 agonist Substances 0.000 title claims 26
- 102100030704 Interleukin-21 Human genes 0.000 title claims 21
- 102000004527 Interleukin-21 Receptors Human genes 0.000 title claims 21
- 108010017411 Interleukin-21 Receptors Proteins 0.000 title claims 21
- 208000026278 immune system disease Diseases 0.000 title claims 5
- 238000000034 method Methods 0.000 claims 42
- 230000001270 agonistic effect Effects 0.000 claims 10
- 201000006417 multiple sclerosis Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 4
- 229960002930 sirolimus Drugs 0.000 claims 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 229960000681 leflunomide Drugs 0.000 claims 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229960000235 temsirolimus Drugs 0.000 claims 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 1
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000047918 Myelin Basic Human genes 0.000 claims 1
- 102000006386 Myelin Proteins Human genes 0.000 claims 1
- 108010083674 Myelin Proteins Proteins 0.000 claims 1
- 101710107068 Myelin basic protein Proteins 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003776 glatiramer acetate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 210000003007 myelin sheath Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45692003P | 2003-03-21 | 2003-03-21 | |
| US60/456,920 | 2003-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005132458A true RU2005132458A (ru) | 2006-03-20 |
Family
ID=33098171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005132458/13A RU2005132458A (ru) | 2003-03-21 | 2004-03-22 | Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20060159655A1 (enExample) |
| EP (1) | EP1608315A4 (enExample) |
| JP (1) | JP2006523682A (enExample) |
| KR (1) | KR20060015482A (enExample) |
| CN (1) | CN1849131A (enExample) |
| AU (1) | AU2004224277A1 (enExample) |
| BR (1) | BRPI0408523A (enExample) |
| CA (1) | CA2518854A1 (enExample) |
| CO (1) | CO5611161A2 (enExample) |
| CR (1) | CR7994A (enExample) |
| EC (1) | ECSP056027A (enExample) |
| IL (1) | IL198102A0 (enExample) |
| MX (1) | MXPA05010035A (enExample) |
| NO (1) | NO20054343L (enExample) |
| RU (1) | RU2005132458A (enExample) |
| WO (1) | WO2004084835A2 (enExample) |
| ZA (1) | ZA200507235B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2504552C2 (ru) * | 2007-12-07 | 2014-01-20 | Займодженетикс, Инк. | Моноклональные антитела против il-21 человека |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| KR20050037552A (ko) | 2002-07-15 | 2005-04-22 | 와이어쓰 | Ｔ 헬퍼(ｔｈ) 세포 발생 및 기능을 조절하는 방법 및조성물 |
| JP4914209B2 (ja) | 2003-03-14 | 2012-04-11 | ワイス | ヒトｉｌ−２１受容体に対する抗体および該抗体の使用 |
| US7276478B2 (en) * | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
| BRPI0510996A (pt) * | 2004-05-19 | 2007-12-04 | Wyeth Corp | métodos para melhorar um sintoma de um distúrbio atópico, e para tratar ou prevenir um distúrbio atópico em um paciente, métodos para modular a produção de igg e ige em uma célula, e nìveis relativos de ige e igg, composição farmacêutica, recipiente, métodos para avaliar um paciente tendo ou suspeito de ter um distúrbio atópico, e para avaliar um paciente quanto ao risco de um distúrbio atópico |
| US20060039902A1 (en) * | 2004-08-05 | 2006-02-23 | Young Deborah A | Antagonizing interleukin-21 receptor activity |
| GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| ATE497975T1 (de) | 2005-04-18 | 2011-02-15 | Novo Nordisk As | Il-21-varianten |
| AU2006341398B9 (en) * | 2005-11-28 | 2012-02-02 | Zymogenetics, Inc. | IL-21 receptor antagonists |
| JP5322653B2 (ja) * | 2005-11-28 | 2013-10-23 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２１アンタゴニスト |
| WO2009100035A2 (en) * | 2008-02-01 | 2009-08-13 | Wyeth | Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
| PE20100141A1 (es) | 2008-05-23 | 2010-02-22 | Wyeth Corp | Proteina de union al receptor de interleuquina 21 |
| AR072136A1 (es) * | 2008-05-23 | 2010-08-11 | Wyeth Corp | Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21 |
| US20100075329A1 (en) * | 2008-09-23 | 2010-03-25 | O'toole Margot | Methods for predicting production of activating signals by cross-linked binding proteins |
| ES2784830T3 (es) * | 2008-10-08 | 2020-10-01 | Cambridge Entpr Ltd | Métodos para el diagnóstico y tratamiento de enfermedad autoinmune como consecuencia de esclerosis múltiple |
| US20110293700A1 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| SI2665486T1 (sl) | 2011-01-18 | 2020-07-31 | Bioniz, Llc | Sestavki za moduliranje aktivnosti gama-C-citokina |
| WO2012112933A1 (en) * | 2011-02-18 | 2012-08-23 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
| WO2017062685A1 (en) | 2015-10-09 | 2017-04-13 | Bioniz, Llc | Modulating gamma - c -cytokine activity |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| WO2020009437A1 (ko) * | 2018-07-04 | 2020-01-09 | 서울대학교산학협력단 | 신경손상의 면역세포치료 |
| CN120535649A (zh) | 2018-08-30 | 2025-08-26 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| NZ772550A (en) | 2018-08-30 | 2025-08-29 | Immunitybio Inc | Multi-chain chimeric polypeptides and uses thereof |
| CN112888445B (zh) | 2018-08-30 | 2025-06-10 | 免疫生物公司 | 治疗老年化相关病症的方法 |
| WO2020227019A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| KR20220035394A (ko) | 2019-06-21 | 2022-03-22 | 에이치씨더블유 바이올로직스, 인크. | 다중-사슬 키메라 폴리펩티드 및 이의 용도 |
| WO2021163298A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| AU2021220870A1 (en) | 2020-02-11 | 2022-08-04 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| KR20230031280A (ko) | 2020-06-01 | 2023-03-07 | 에이치씨더블유 바이올로직스, 인크. | 노화 관련 장애의 치료 방법 |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| EP4646225A1 (en) * | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010025022A1 (en) * | 1997-11-26 | 2001-09-27 | Kikly Kristine Kay | Hnovilr |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US20030003545A1 (en) * | 1998-05-29 | 2003-01-02 | Reinhard Ebner | Interleukins-21 and 22 |
| WO2000008152A1 (en) * | 1998-08-04 | 2000-02-17 | Regeneron Pharmaceuticals, Inc. | Novel orphan cytokine receptors |
| US6576744B1 (en) * | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US20020090680A1 (en) * | 1999-05-18 | 2002-07-11 | Millennium Pharmaceuticals, Inc. | Novel IL-9/IL-2 receptor-like molecules and uses thereof |
| AU2001253127A1 (en) * | 2000-04-05 | 2001-10-23 | Zymogenetics Inc. | Soluble zalpha11 cytokine receptors |
| EP3254687A1 (en) * | 2001-10-04 | 2017-12-13 | Genetics Institute LLC | Methods and compositions for modulating interleukin-21 receptor activity |
| DE60233888D1 (de) * | 2001-11-05 | 2009-11-12 | Zymogenetics Inc | Il-21-antagonisten |
| AU2003226141A1 (en) * | 2002-03-27 | 2003-10-13 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for treating cancer in humans |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| PT1531850E (pt) * | 2002-06-07 | 2012-05-07 | Zymogenetics Inc | Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos |
| KR20050037552A (ko) * | 2002-07-15 | 2005-04-22 | 와이어쓰 | Ｔ 헬퍼(ｔｈ) 세포 발생 및 기능을 조절하는 방법 및조성물 |
| JP4914209B2 (ja) * | 2003-03-14 | 2012-04-11 | ワイス | ヒトｉｌ−２１受容体に対する抗体および該抗体の使用 |
| BRPI0510996A (pt) * | 2004-05-19 | 2007-12-04 | Wyeth Corp | métodos para melhorar um sintoma de um distúrbio atópico, e para tratar ou prevenir um distúrbio atópico em um paciente, métodos para modular a produção de igg e ige em uma célula, e nìveis relativos de ige e igg, composição farmacêutica, recipiente, métodos para avaliar um paciente tendo ou suspeito de ter um distúrbio atópico, e para avaliar um paciente quanto ao risco de um distúrbio atópico |
| US20060039902A1 (en) * | 2004-08-05 | 2006-02-23 | Young Deborah A | Antagonizing interleukin-21 receptor activity |
| US7533965B2 (en) * | 2005-03-07 | 2009-05-19 | Eastman Kodak Company | Apparatus and method for electrostatically charging fluid drops |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis |
-
2004
- 2004-03-22 MX MXPA05010035A patent/MXPA05010035A/es unknown
- 2004-03-22 KR KR1020057017652A patent/KR20060015482A/ko not_active Withdrawn
- 2004-03-22 RU RU2005132458/13A patent/RU2005132458A/ru unknown
- 2004-03-22 EP EP04758055A patent/EP1608315A4/en not_active Withdrawn
- 2004-03-22 CA CA002518854A patent/CA2518854A1/en not_active Abandoned
- 2004-03-22 JP JP2006507478A patent/JP2006523682A/ja active Pending
- 2004-03-22 US US10/806,611 patent/US20060159655A1/en not_active Abandoned
- 2004-03-22 BR BRPI0408523-0A patent/BRPI0408523A/pt not_active IP Right Cessation
- 2004-03-22 WO PCT/US2004/008833 patent/WO2004084835A2/en not_active Ceased
- 2004-03-22 ZA ZA200507235A patent/ZA200507235B/en unknown
- 2004-03-22 AU AU2004224277A patent/AU2004224277A1/en not_active Abandoned
- 2004-03-22 CN CNA2004800076306A patent/CN1849131A/zh active Pending
-
2005
- 2005-09-16 CR CR7994A patent/CR7994A/es not_active Application Discontinuation
- 2005-09-20 NO NO20054343A patent/NO20054343L/no not_active Application Discontinuation
- 2005-09-20 EC EC2005006027A patent/ECSP056027A/es unknown
- 2005-09-21 CO CO05095726A patent/CO5611161A2/es unknown
-
2009
- 2009-04-07 IL IL198102A patent/IL198102A0/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2504552C2 (ru) * | 2007-12-07 | 2014-01-20 | Займодженетикс, Инк. | Моноклональные антитела против il-21 человека |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1608315A4 (en) | 2008-07-16 |
| AU2004224277A1 (en) | 2004-10-07 |
| KR20060015482A (ko) | 2006-02-17 |
| BRPI0408523A (pt) | 2006-03-21 |
| CA2518854A1 (en) | 2004-10-07 |
| CO5611161A2 (es) | 2006-02-28 |
| US20060159655A1 (en) | 2006-07-20 |
| WO2004084835A3 (en) | 2006-05-26 |
| NO20054343L (no) | 2005-11-24 |
| JP2006523682A (ja) | 2006-10-19 |
| CN1849131A (zh) | 2006-10-18 |
| NO20054343D0 (no) | 2005-09-20 |
| ECSP056027A (es) | 2006-09-18 |
| EP1608315A2 (en) | 2005-12-28 |
| WO2004084835A2 (en) | 2004-10-07 |
| IL198102A0 (en) | 2009-12-24 |
| CR7994A (es) | 2006-10-17 |
| ZA200507235B (en) | 2007-03-28 |
| MXPA05010035A (es) | 2005-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005132458A (ru) | Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21 | |
| JP2006523682A5 (enExample) | ||
| Li et al. | Delayed microglial depletion after spinal cord injury reduces chronic inflammation and neurodegeneration in the brain and improves neurological recovery in male mice | |
| Aharoni et al. | The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice | |
| Tobinick et al. | TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study | |
| Okiyama et al. | Therapeutic effects of interleukin‐6 blockade in a murine model of polymyositis that does not require interleukin‐17A | |
| Ambrosini et al. | Astrocytes are the major intracerebral source of macrophage inflammatory protein‐3α/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro | |
| Soriano et al. | IL-1β biological treatment of familial Mediterranean fever | |
| Dirice et al. | Soluble factors secreted by T cells promote β-cell proliferation | |
| US20090092604A1 (en) | Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity | |
| Kanakasabai et al. | Peroxisome proliferator‐activated receptor δ agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis | |
| Adorini et al. | Pathogenesis and immunotherapy of autoimmune diseases | |
| US20110002928A1 (en) | Uses of Mammalian Cytokine; Related Reagents | |
| CN108310376A (zh) | 用于治疗类风湿性关节炎的组合物及其使用方法 | |
| JP2013227340A (ja) | 可溶性リンホトキシンβレセプターによる脱髄障害の処置 | |
| MXPA05012497A (es) | Composiciones y metodos para el tratamiento del sindrome respiratorio agudo severo (sars). | |
| Kanakasabai et al. | PPARδ deficient mice develop elevated Th1/Th17 responses and prolonged experimental autoimmune encephalomyelitis | |
| Baker Jr et al. | Immunological aspects of cancers arising from thyroid follicular cells | |
| Rabin et al. | Mechanistic aspects of stressor-induced immune alteration | |
| JP2013535694A (ja) | 神経病理学的疾患の検出および調節におけるｔａｍ受容体およびｔａｍ受容体リガンド | |
| US20120076793A1 (en) | Agent for promoting hepatic cell replication and agent for improving insulin resistance | |
| KR20250011948A (ko) | 인터류킨-17(il-17) 길항제를 사용하여 건병증을 선택적으로 치료하는 방법 | |
| KR20010024549A (ko) | Ｔｎｆ 길항제의 패혈증 치료를 위한 약제로서의 용도 | |
| JP2007505141A (ja) | Ｃｄ９９アンタゴニストを用いる慢性関節リウマチの処置 | |
| KR20040030948A (ko) | 과민성 질환에 효과적인 ｉｌ-18 저해물질 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA91 | Application withdrawn (on applicant's request) |
Effective date: 20090825 |